HCC

The application is supported by the phase 3 CheckMate -9DW study, and the FDA has set a target action date of April 21, 2025.

During a Case-Based Roundtable® event, Pierre Gholam moderated a discussion on how to proceed with a patient presenting with a LI-RADS 5 mass suspected of being hepatocellular carcinoma.

The FDA has given positive feedback on the planned phase 3 study for the combination of amezalpat, atezolizumab, and bevacizumab in the first-line treatment of unresectable or metastatic hepatocellular carcinoma.

A phase 1 trial is evaluating treatment with MT-303 in patients with hepatocellular carcinoma to determine its safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy.

With extended follow-up, the combination of investigational agents rivoceranib and camrelizumab demonstrated a significant survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

The combination of camrelizumab and rivoceranib significantly improved survival rates in patients with unresectable liver cancer compared with standard treatment.

During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.

In a retrospective study in patients with hepatocellular carcinoma, 40% of patients developed irAEs after receiving the first and second doses of immunotherapy.

In the frontline, patient body mass index plays a prognostic role when using atezolizumab plus bevacizumab vs lenvatinib for patients with advanced hepatocellular carcinoma.

No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable hepatocellular carcinoma.

The phase 3 CheckMate -9DW study of frontline nivolumab plus ipilimumab in hepatocellular cancer met its primary end point of overall survival vs sorafenib or lenvatinib.

In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.

In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.

The FDA granted a fast track designation to BST02 for patients with all forms of liver cancer.

Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.

Fostroxacitabine bralpamide combined with lenvatinib showed acceptable safety and tolerability, while inducing promising efficacy in patients with hepatocellular carcinoma.

The frontline use of pembrolizumab plus lenvatinib in patients with advanced HCC showed a 3-year or more response among 35% of responders; however, additional efficacy results remained consistent with previous findings from the phase 3 LEAP-002 trial.

Research is ongoing to identify biomarkers in hepatocellular carcinoma that are predictive in nature, according to Richard Kim, MD.

At a live virtual event Richard Kim, MD, discussed treating patients with hepatocellular carcinoma and how the treatment approach to this disease has changed.

Recent findings identified that overall and cancer-specific mortality risks were lowered in patients who used antidepressants following a diagnosis with hepatocellular carcinoma compared with patients that did not.

At 2 separate Case-Based Roundtable events, oncologists discussed important factors that could influence their choice of frontline therapy for a patient with advanced hepatocellular carcinoma.

THIO has received 2 prior orphan drug designations, and the agent has shown promise in preclinical studies for the treatment of glioblastoma.

The phase 3 EMERALD-1 trial has met its primary end point and continues to assess durvalumab combined with transarterial chemoembolization and bevacizumab for the secondary end point of overall survival in patients with hepatocellular carcinoma.

Encouraging progression-free survival and ctDNA molecular response rates were seen with SD-101 delivered via pressure-enabled drug delivery plus intravenous checkpoint inhibitors in patients with metastatic uveal melanoma with liver metastases.

In an interview with Targeted Oncology, Rachna T. Shroff, MD, MS, FASCO, discussed new systemic therapies that are available or being developed to treat patients with intrahepatic cholangiocarcinoma.

October is Liver Cancer Awareness Month, and strides continue to be made in the realm of liver cancer diagnosis and treatment. Two experts, Joan Culpepper-Morgan, MD, and Susanne G. Warner, MD, shed light on some of the treatment options available in the space.

In an interview with Targeted Oncology during the International Liver Cancer Association Annual Conference 2023, Tim F. Greten, MD, discussed the key highlights from his presentation on tissue biopsy, and his thoughts on the opposing argument in favor of liquid biopsy.

Tislelizumab met its primary end point of overall survival and exceeded that of sorafenib in patients with unresectable hepatocellular carcinoma.

At median follow-ups of 9.2 and 9.9 months in a phase 1b/2 study, the confirmed objective response rate with the TPST-1120 triplet was 30% vs 13.3% in the control arm, respectively.